News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Hongcheng Zhu: Multidisciplinary management of N2 stage III NSCLC
Hongcheng Zhu/X
Mar 25, 2025, 18:29

Hongcheng Zhu: Multidisciplinary management of N2 stage III NSCLC

Hongcheng Zhu, Radiation and Clinical Oncologist at Fudan University Shanghai Cancer Center, shared a post on X:

“It was a year ago at ELCC24 in Prague, when I have an opportunity to meet the panel of multidisciplinary group exploring management of N2 NSCLC. Now our review finally out before ELCC25!

Really looking forward the inspirations in Paris this year!”

Hongcheng Zhu

More posts featuring ELCC24.

cancer ELCC24 ELCC25 Hongcheng Zhu Lung cancer NSCLC OncoDaily Oncology
Special Coverage
Insight
Jun 19, 2025, 23:42
Chadi Hage Chehade: Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer 
Blog
Jun 19, 2025, 17:36
ESTRO Introduces KAYAC+ to Advance Radiation Therapy For Adolescents And Young Adults With Cancer
Blog
Jun 19, 2025, 17:26
XVII CCI LATAM Conference Was a Celebration Of a Growing Community, Unity, and Hope - Childhood Cancer International
Blog
Jun 19, 2025, 17:07
Join The AI For Everyone, Everywhere, Let’s talk about Large Language Models Meeting - SIOP
Blog
Jun 19, 2025, 16:57
David Planchard: We Need to Work Together to Develop The Wave of New Treatments That Is Coming For Our Patients
Blog
Jun 19, 2025, 16:21
Neeraj Agarwal: Poor Outcomes with SOC in mHSPC Prostate Cancer Patients With HRR Mutation
Blog
Jun 19, 2025, 16:12
World Kidney Cancer Day 2025: Uniting for Progress in the Fight Against Renal Cell Carcinoma
Blog
Jun 19, 2025, 16:01
IARC Marks World Kidney Cancer Day with New Video and Project Highlights
Science
Jun 19, 2025, 15:50
Alexey Kulikov Shared An Article on Cancer Vaccines and The Future of Immunotherapy
Opinion
Jun 19, 2025, 15:47
Mostafa Faisal: Primary Refractory AML and Allo-HCT - A 10-Year Retrospective Study from Japan
Blog
Jun 19, 2025, 15:36
Amol Akhade: KEYNOTE-689 - A Turning Point in Resectable HNSCC - Or a Cautious Step Forward?
Drugs
Jun 19, 2025, 15:30
Graham Collins: Nivo-AVD vs BV-AVD in Older Patients (60+) with Hodgkin Lymphoma